Addenda Capital Inc. Sells 1,510 Shares of Pfizer Inc. $PFE

Addenda Capital Inc. lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 0.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 254,203 shares of the biopharmaceutical company’s stock after selling 1,510 shares during the quarter. Addenda Capital Inc.’s holdings in Pfizer were worth $6,162,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. GKV Capital Management Co. Inc. acquired a new position in Pfizer during the first quarter valued at approximately $27,000. Bayforest Capital Ltd acquired a new position in Pfizer during the first quarter worth $28,000. North Capital Inc. acquired a new position in Pfizer during the first quarter worth $28,000. WPG Advisers LLC acquired a new position in Pfizer during the first quarter worth $35,000. Finally, Horizon Financial Services LLC bought a new stake in Pfizer during the first quarter worth $35,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 0.6%

Pfizer stock opened at $23.75 on Friday. The firm has a 50 day moving average price of $24.55 and a two-hundred day moving average price of $24.13. The firm has a market cap of $135.03 billion, a price-to-earnings ratio of 12.63, a PEG ratio of 0.77 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the previous year, the firm earned $0.60 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on PFE shares. Bank of America upped their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Citigroup increased their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday. Finally, Morgan Stanley increased their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.